Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909976 | 0.71 | TSHR (0.36) | TSHR | |
| SCHEMBL2732710 | 0.71 | — | — | |
| SCHEMBL8890 | 0.67 | TSHR (0.48) | TSHR | |
| SCHEMBL17581766 | 0.67 | TSHR (0.31) | TSHR | |
| SCHEMBL6306532 | 0.66 | MAOA (0.39) | — | |
| SCHEMBL151022 | 0.65 | TSHR (0.46) | TSHR | |
| SCHEMBL152117 | 0.65 | TSHR (0.46) | TSHR | |
| SCHEMBL62944 | 0.65 | TSHR (0.46) | TSHR | |
| SCHEMBL2783970 | 0.64 | CYP1A2 (0.36) | — | |
| SCHEMBL24682 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020189209-A1 | LIQUID CRYSTAL COMPOSITE BODY AND LIQUID CRYSTAL LIGHT CONTROL ELEMENT | JNC株式会社 | 2020-09-24 | — | — | WO | claimed |
| WO-2020189208-A1 | LIQUID CRYSTAL COMPOSITE AND LIQUID CRYSTAL DIMMING ELEMENT | JNC株式会社 | 2020-09-24 | — | — | WO | claimed |
| US-10640709-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-05 | — | — | US | claimed |
| US-20180163133-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-14 | — | — | US | claimed |
| US-20150093435-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARC1, INC. | 2015-04-02 | — | — | US | claimed |
| US-8026266-B2 | Treatment of length dependent neuropathy | ARCION THERAPEUTICS, INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-20110142920-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARCION THERAPEUTICS, INC. | 2011-06-16 | — | — | US | claimed |
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| EP-1962836-A2 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | Arcion Therapeutics, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070142385-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARC1, INC. | 2007-06-21 | — | — | US | claimed |
| WO-2007056460-A2 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARCION THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-4265911-A | Propionamidoxime derivatives | SYNTHELABO (FR) | 1981-05-05 | — | — | US | claimed |
| US-11344498-B2 | Compositions and methods for on-demand high-efficiency triggerable anesthesia | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2020189209-A1 | LIQUID CRYSTAL COMPOSITE BODY AND LIQUID CRYSTAL LIGHT CONTROL ELEMENT | JNC株式会社 | 2020-09-24 | — | — | WO | disclosed |
| WO-2020189208-A1 | LIQUID CRYSTAL COMPOSITE AND LIQUID CRYSTAL DIMMING ELEMENT | JNC株式会社 | 2020-09-24 | — | — | WO | disclosed |
| US-10640709-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-05 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6559186-B1 | Pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2- adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic | ARC 1, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1191028-A1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093435-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | TSHR 2210/4885 |
| US-20110142920-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | TSHR 2210/4885 |
| US-11344498-B2 | Compositions and methods for on-demand high-efficiency triggerable anesthesia | CACNB1, CACNA1S, CACNA1D | TSHR 1327/4885 |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | TSHR 2844/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | TSHR 1480/4885 |
| US-20070142385-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | TSHR 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.